BD2 domain selective BET inhibitor

orally efficacious in XG w/o platelet, GI tox

from SBDD of BD1/2 dual inhibitors

Nature, 2020, 578, 306-310

AbbVie, North Chicago, IL

ABBV-744

ABBV-744 (AbbVie oral in vivo BD2 domain selective BET inhibitor)


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: